Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT03420118

Study of Biomarkers in Gynecological Cancers

Led by University Health Network, Toronto · Updated on 2025-12-05

1000

Participants Needed

1

Research Sites

521 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In recent years, there has been a significant improvement in understanding the biology of cancer and this information has been used to improve cancer care and patient outcome. Research has shown that changes in some genes and/or proteins may be important indicators for certain cancers and response to treatments. Genes are molecules made up of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). DNA contain instructions for the development and functioning of the cells in the body and are passed down from parent to child. RNA is involved with producing proteins in the body. Further research is needed to better understand the changes found in cancer cells and how to target them to stop or reduce cancer growth. A drug that may be able to block certain specific cancer cell changes is called "targeted therapy". Different people with the same type of cancer receiving the same drug could have different responses to it. For example, one person may experience a reduction of their tumor while another person's cancer may worsen. The reason for this is still not well understood and could lie in gene changes. Understanding these changes may allow researchers to predict how treatments may work in guiding decisions around choice of drugs. The purpose of the study is to learn more about gene changes or protein expression (levels) of tumors to better understand the behavior of gynecological diseases and, if possible, better address participants' cancer care now or in the future.

CONDITIONS

Official Title

Study of Biomarkers in Gynecological Cancers

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with probable or confirmed gynecological malignancy including ovarian, tubal, peritoneal, uterine, cervical, vulvar, vaginal, and rare gynecological cancers
  • Age 16 years or older at time of consent
  • Ability to understand and provide written informed consent
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less
  • Consent to provide tissue samples from surgery or biopsy and blood samples
  • Life expectancy of at least 3 months
Not Eligible

You will not qualify if you...

  • Patients with prior neoadjuvant chemotherapy or radiation treatment for newly diagnosed gynecological cancer
  • Any contraindications to tumor biopsy or blood collection procedures
  • Diagnosis of high grade serous ovarian cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Princess Margaret Cancer Centre

Toronto, Ontario, Canada, M5G 1Z5

Actively Recruiting

Loading map...

Research Team

A

Amit Oza, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here